Cullinan Oncology Llc Stock Revenue
| CGEM Stock | USD 13.09 0.32 2.51% |
Cullinan Oncology LLC fundamentals help investors to digest information that contributes to Cullinan Oncology's financial success or failures. It also enables traders to predict the movement of Cullinan Stock. The fundamental analysis module provides a way to measure Cullinan Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cullinan Oncology stock.
| Last Reported | Projected for Next Year |
Cullinan | Revenue |
Cullinan Oncology LLC Company Revenue Analysis
Cullinan Oncology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Cullinan
Projected quarterly revenue analysis of Cullinan Oncology LLC provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Cullinan Oncology match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Cullinan Oncology's stock price.
Cullinan Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Cullinan Oncology is extremely important. It helps to project a fair market value of Cullinan Stock properly, considering its historical fundamentals such as Revenue. Since Cullinan Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cullinan Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cullinan Oncology's interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Cullinan Oncology LLC reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Cullinan Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cullinan Oncology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cullinan Oncology could also be used in its relative valuation, which is a method of valuing Cullinan Oncology by comparing valuation metrics of similar companies.Cullinan Oncology is currently under evaluation in revenue category among its peers.
Cullinan Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cullinan Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cullinan Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Cullinan Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Cullinan Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cullinan Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cullinan Oncology's value.| Shares | Alliancebernstein L.p. | 2024-06-30 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.7 M | Holocene Advisors, Lp | 2024-09-30 | 1.5 M | Vr Adviser, Llc | 2024-09-30 | 1.4 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | Braidwell Lp | 2024-09-30 | 1.2 M | Orbimed Advisors, Llc | 2024-06-30 | 1.1 M | Nextech Invest Ag | 2024-09-30 | 1.1 M | Mpm Oncology Impact Management Lp | 2024-09-30 | 7.6 M | Bvf Inc | 2024-09-30 | 5.8 M |
Cullinan Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 186.57 M | ||||
| Shares Outstanding | 58.23 M | ||||
| Shares Owned By Insiders | 4.49 % | ||||
| Shares Owned By Institutions | 95.51 % | ||||
| Number Of Shares Shorted | 8.71 M | ||||
| Price To Earning | 5.23 X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 26.88 X | ||||
| Gross Profit | 18.94 M | ||||
| EBITDA | (190.34 M) | ||||
| Net Income | (153.16 M) | ||||
| Cash And Equivalents | 611 M | ||||
| Cash Per Share | 13.40 X | ||||
| Total Debt | 3.59 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 10.04 X | ||||
| Book Value Per Share | 10.80 X | ||||
| Cash Flow From Operations | (134.28 M) | ||||
| Short Ratio | 18.00 X | ||||
| Earnings Per Share | (2.84) X | ||||
| Target Price | 33.0 | ||||
| Number Of Employees | 85 | ||||
| Beta | -0.12 | ||||
| Market Capitalization | 762.2 M | ||||
| Total Asset | 484.18 M | ||||
| Retained Earnings | (200.86 M) | ||||
| Working Capital | 452.05 M | ||||
| Net Asset | 484.18 M |
About Cullinan Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cullinan Oncology LLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cullinan Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cullinan Oncology LLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Cullinan Oncology Piotroski F Score and Cullinan Oncology Altman Z Score analysis. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.